Nanospectra Biosciences

Nanospectra Biosciences is a private medical device company that has pioneered a patient-centered nanomedicine approach to selective thermal ablation therapy. The company's lead product, AuroLase, is the first ultra-focal therapy for prostate cancer. Nanospectra's ultra-focal method maximizes treatment efficacy while minimizing side effects associated with current therapies, including surgery, radiation, and alternative focal therapies. Implementing a multi-pronged growth strategy, Nanospectra focuses on clinical development, exclusive cooperative agreements, and ongoing research and development.